SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today ...

Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient in a ...

SolasCure, a Cambridge biotech developing a novel treatment to transform chronic wound healing, has initiated a new Phase II ...

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...

Reports Q4 revenue $ $27.87M consensus $23.5M…”2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage and ...

The clinical-stage company on Monday said that, following "highly encouraging" 16-week extension results from the Phase 2b trial, it believes it has established proof-of-concept for neflamapimod as a ...

In March 2025, Beckley Psytech completed patient enrollment in the eight-week, double-blind, core stage of the global Phase ...

Topas Therapeutics today announced the publication of data highlighting the ability of its proprietary antigen-coupled nanoparticles' to achieve tolerance induction in relevant autoimmune disease ...

Contineum Therapeutics, Inc. (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology ...

While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

On 3 April 2024, the Company announced publication of the results of the RED DESERT and SAHARA proof-of-concept studies, in the prestigious peer-reviewed journal European Journal of Heart Failure.